These ovarian cancer cell lines are of low (OVCAR4), moderate (PEO4), and high (SKOV3) HER2 expression status [34], in addition to having variable expression levels of HER3, the key dimerization partner of HER2 in the order PEO4>OVCAR4>SKOV3 [34]., We found that at least part of mechanism of action of the HER2 targeted immunotherapeutic agents involved generation of ROS, which contributed to the killing effects and cancer growth retardation. This evidence concerns the gene ERBB3 and ovarian carcinoma.